MIMETAS Makes Cancer-on-a-Chip A Reality

Visit booth 4057 for the latest in microfluidic 3D cell culture technology

22 Mar 2019
Matthew Mcardle

MIMETAS, the organ-on-a-chip company, will be at the AACR Annual Meeting 2019 in Atlanta, Georgia to present to researchers in the oncology fields the powerful possibilities of advanced 3D cell culture with its innovative products. The company will be announcing the first 3D culture chip to vascularize tissues, from spheroids and organoids to patients’ biopsies and PDX material. This new product will enable researchers to mimic the tumor microenvironment in vitro by grafting tumor tissue in a 3D natural tissue environment.

You can visit MIMETAS at booth 4057 to learn more.

Furthermore, the company will present three posters:

A novel high-throughput microfluidic drug screening platform using pancreatic ductal adenocarcinoma derived organoids
Poster board: #13
Session: Tumor Biology
Session Title: 3D Models
Date: Sunday, March 31, 1:00 PM - 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B

A novel high-throughput platform for head & neck cancer organoids drug screening
Poster board: #22
Session: Tumor Biology
Session Title: Regulation of Cancer Stem Cell Stemness, Epithelial-Mesenchymal Transition, and the Microenvironment
Date: Monday, April 1, 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B

A Racially/Ethnically Diverse 3D PDX Model of Prostate Cancer
Poster board: #3
Session: Science and Health Policy
Session Title: Science and Health Policy 1
Date: Tuesday, April 2, 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 29

See MIMETAS publications for more details and our AACR feature page for ongoing coverage from the show floor.

Links

Tags